Quanterix Corporation (NASDAQ: QTRX) announced the launch of its Content Innovation Engine at the American Association for Cancer Research Annual Meeting 2026. The platform combines Akoya Biosciences' spatial biology technology with Quanterix's immunoassay development capabilities to support cancer research applications.

The Content Innovation Engine integrates spatial instrumentation with assay design and reagent formulation systems intended for translational and clinical research settings. The platform is structured around cancer biology frameworks to analyze tissue sections.

"Spatial biology has fundamentally changed how we see cancer," said Everett Cunningham, President and CEO of Quanterix. "What Quanterix brings is the assay expertise, quality systems, and scale to carry that science further, into translational settings, into the clinic, into decisions that affect patients."

The company's PhenoCode Discovery IO60 panel received finalist recognition in the Edison Awards. Quanterix introduced an IO60 Spike-In Module that covers checkpoint therapy markers including PD-1/PD-L1 and CTLA-4, as well as tertiary lymphoid structure markers.

The company debuted new antibody-drug conjugate content compatible with existing panels, enabling measurement of target expression and immune response in single tissue sections. This addresses research demand for combination therapy analysis.

Quanterix introduced the PhenoCode Molecular Barcoding Kit, built on PhenoCode 2.0 chemistry, which allows researchers to barcode antibodies for expanded panel applications. Early access begins in May 2026.

The company also presented two new lung cancer panels for its PhenoImager HT platform through its Accelerator Service Lab, building on previous breast cancer panel offerings.

At AACR 2026, more than 25 research posters from Quanterix customers and collaborators presented data generated using the company's PhenoCycler-Fusion and PhenoImager HT platforms across various cancer research applications.